EFTR — eFFECTOR Therapeutics, Inc.
$0.00
+$0.00 (+0.00%)
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company's lead product candidate includes Zotatifin, an inhibitor of eIF4A, which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as has completed Phase 2 clinical trial in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer.
Market Cap
$3763.00
Forward P/E
-0.0x
52-Week Range
N/A
EFTR Price History
Revenue vs. Net Income
$0
Revenue · FY2023
Annual. Net margin is shown under each year.
Free Cash Flow
-$29.6M
FCF · FY2023
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-242.8%
ROCE · FY2023 (approx.)
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
0.8x
Assets ÷ liabilities · FY2023
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
5.4%
CapEx · FY2022
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+32.8%
Dilution · FY2023
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
